Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL – 2024

Aim: To systematize and comprehensively analyze scientific sources and studies on metabolic-associated steatotic liver disease (MASLD) based on materials from the European Congress of the European Association for the Study of the Liver (EASL – 2024). Materials and Methods: This paper analyzes the current scientific research on the prevalence, pathogenesis, diagnostic methods, prognosis, and pharmacotherapy of MASLD presented at the EASL 2024 Congress. The following methods were used in the preparation of the work: a systematic approach and bibliosemantic analysis. Conclusions: Studies on the pathogenesis of MASLD progression confirm the significant role of insulin resistance and hyperinsulinemia in increasing hepatocyte cytolysis activity, raising the concentration of cytokeratin CK-18, HbA1c, low-density lipoproteins, triglycerides, and the severity of fibrosis (FIB-4). EASL 2024 studies evaluated the diagnostic efficiency of non-invasive methods for assessing steatosis and liver fibrosis severity in MASLD (FIB-4, FibroScan®, Enhanced Liver Fibrosis (ELF), Vibration Controlled Transient Elastography (VCTE), LiverPRO, etc.). Due to the high prevalence of steatotic liver disease, comorbidities such as chronic viral hepatitis C, autoimmune hepatitis, and alcoholic liver disease – contributing to liver fibrosis progression and hepatocellular carcinoma – are significant. Promising drugs for MASLD treatment include resmethyrom, fibroblast growth factor 21 analogs (including pegosafermin), and pemvidutide, a long-acting, balanced GLP-1/glucagon dual receptor agonist.